William E. Martin III is a seasoned biotechnology executive with over three decades of experience in the life sciences industry. He founded TriLink BioTechnologies, Inc. in 1996, pioneering advancements in oligonucleotide synthesis and modified nucleosides critical for gene therapy and mRNA applications. Under his leadership as President and CEO, TriLink evolved from a startup into a global leader, serving major pharmaceutical and biotech companies with high-quality custom nucleic acids. Martin's visionary approach positioned the company at the forefront of emerging therapeutic modalities, including RNA interference and messenger RNA technologies. In 2020, TriLink's acquisition by Maravai LifeSciences Holdings, Inc., marked a pivotal expansion, with Martin assuming the role of Chief Executive Officer of the newly formed public company following its SPAC merger. As CEO, he spearheaded Maravai's growth into a comprehensive provider of life sciences reagents and services, capitalizing on surging demand during the COVID-19 pandemic. TriLink's CleanCap® mRNA capping technology became essential for vaccine development, contributing to billions in revenue and establishing Maravai as a key supplier to Moderna and other innovators. Martin's tenure as CEO drove remarkable achievements, including scaling production capacity, strategic acquisitions like VectorBuilder, and achieving Nasdaq listing under the ticker MRVI. In 2023, he transitioned to Executive Chairman, continuing to guide the company's innovation in nucleic acid production and bioconjugation solutions. His entrepreneurial legacy has profoundly impacted gene and cell therapy, earning him recognition as a transformative figure in biotech.